ClinicalTrials.gg
CompletedNCT06678074Updated Nov 13, 2026

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

A Phase 1/2 interventional study of Atibuclimab (IC14), 20 mg/kg intravenously, once and Placebo, 150 mL intravenously, once in STEMI, STEMI (ST Elevation MI) and STEMI - ST Elevation Myocardial Infarction (MI), sponsored by Implicit Bioscience. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Implicit Bioscience · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in ST Elevation Myocardial Infarction with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.

Enrollment
50th of 56
7 · median 101
Started
2025
with 3 others
Phase 1/2
2 of 83
none open now
Registered
78th of 83
by date

Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 in phase 1/2, and was the 78th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

6 of the 83 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in ST Elevation Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).

Read the detailed description

Randomized, double-blind, placebo-controlled pilot study to evaluate the safety, exploratory efficacy, and pharmacokinetics of IC14 (atibuclimab) administered via a single IV infusion to patients with STEMI treated with percutaneous intervention. In additional to optional CCR2+ myocardial imaging, biomarkers, cardiac function and patient-reported outcome measures will be reported.

03

Conditions studied

  • STEMI
  • STEMI (ST Elevation MI)
  • STEMI - ST Elevation Myocardial Infarction (MI)
  • Stent Implantation

Keywords

  • atibuclimab
  • IC14
  • monoclonal antibody against CD14
  • anti-CD14
  • antiinflammatory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute myocardial infarction with ST elevation at the J-point in two contiguous leads as determined by .
  2. TIMI grade 0 (no flow) or grade 1 (penetration without perfusion) of the culprit artery on initial coronary angiogram
  3. Symptom onset prior to PCI of ≤12 hours
  4. Planned to receive the local standard of care for treatment of their STEMI and follow up which must include percutaneous coronary intervention (PCI)
  5. Ability to infuse study drug within 12 hours of PCI
  6. Age ≥18 years, willing and able to provide written and to comply with the protocol (i.e., reporting of symptoms)
  7. Capable of completing study visits
  8. Females participating in the study must meet one of the following criteria:

    1. (postmenopausal females must have no menstrual bleeding for at least 1 year);
    2. Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months; or
    3. If not postmenopausal, agree to use a double method of , one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) until 30 days after the treatment
  9. Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) until 30 days after treatment

Exclusion criteria

Exclusion Criteria:

An individual fulfilling any of the following criteria is to be excluded from enrollment in the study:

  1. Killip Classification for Heart Failure Class III (acute pulmonary edema) or IV (cardiogenic shock)
  2. Severe aortic or mitral valve disease
  3. Failure to reperfuse, vascular dissection, cardiac perforation, cardiac arrest, requirement for mechanical circulatory support, or acute respiratory failure requiring ventilatory support
  4. Major hemodynamic instability or uncontrolled ventricular arrhythmias
  5. Planned or conducted thrombolytic therapy for treatment of this STEMI event
  6. Planned or conducted coronary artery bypass graft
  7. Previous major vascular intervention within the last 4 weeks
  8. Major surgery within the last 6 weeks
  9. Evidence of an active gastrointestinal or urogenital bleeding
  10. Recent (\<14 days) use of or anti-inflammatory drugs (including oral at a prednisone equivalent dose of ≥0.5 mg/kg/day but not including inhaled or low-dose oral corticosteroids, non-steroidal anti-inflammatory drugs, or colchicine).
  11. Chronic inflammatory disorder (i.e., rheumatoid arthritis, systemic lupus erythematosus).
  12. Active infection (of any type), including chronic/recurrent infectious disease (including , , and /AIDS), but excluding HCV+ with undetectable plasma RNA.
  13. Neutropenia (\<1,500/mm3 or \<1,000/mm3 in Black/African American patients).
  14. Active , excluding carcinoma in situ [any location] or localized non-melanoma skin cancer
  15. Participation in any study using an drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.
  16. of less than 1 year due to non-cardiac pathology
  17. History of allergic reaction to atibuclimab (IC14), any monoclonal antibody, or any other component used in the study (including contrast media)
  18. Body weight >300 pounds (weight limit of the PET/CT table)
  19. Known severe renal ( \<30 mL/min) or hepatic insufficiency as well as (ALT) elevation ≥ 3x ; isolated AST-elevation is not considered an exclusion criterion from study participation
  20. Any abnormality identified at the time of Screening that in the judgment of the Investigator, or any sub-Investigator would preclude safe completion of the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Experimental drug intervention

    monoclonal antibody against CD14

    Drug: Atibuclimab (IC14), 20 mg/kg intravenously, once

  • Placebo comparator
    Placebo

    Identical-appearing normal saline for injection, intravenous, once

    Other: Placebo, 150 mL intravenously, once

Interventions

  • DrugAtibuclimab (IC14), 20 mg/kg intravenously, once

    Drug page: AtibuclimabStudies of AtibuclimabAtibuclimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    monoclonal antibody against CD14

  • OtherPlacebo, 150 mL intravenously, once

    sterile normal saline for injection

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (safety and tolerability)

    Treatment-emergent adverse events

    Time frame: Day 1-29

Secondary outcomes

  1. CCR2+ cell myocardial infiltration (optional)

    Characterization of CCR2+ cell myocardial infiltration mean standard uptake value (SUVmean) and change from 48 hours measured by myocardial PET/CT imaging at Day 15

    Time frame: 48 hours and Day 15

  2. Biomarker C-Reactive Protein

    Change from baseline

    Time frame: Day 4, 15, 29

  3. Biomarker White Blood Cell Count

    Change from baseline

    Time frame: Day 4, 15, and 29

  4. Biomarker Fibrinogen

    Change from baseline

    Time frame: Day 4, 15, 29

  5. Biomarker Interleukin 6

    Change from baseline

    Time frame: Day 4, 15, and 29

  6. Biomarker Interleukin-1

    change from baseline

    Time frame: Day 4, 15, and 29

  7. Biomarker Troponin I

    change from baseline

    Time frame: Day 4, 15, and 29

  8. Single-cell RNASeq

    change from baseline

    Time frame: Day 4, 15, and 29

  9. Cardiac death or readmission for heart failure

    * Cardiac death defined as death due to acute MI, sudden cardiac death, HF, stroke, cardiovascular procedure, cardiovascular hemorrhage, or other cardiovascular cause. * Heart failure readmission, defined as an event in which the patient is admitted to the hospital with a primary diagnosis of HF, the length of stay is at least 24 hours (or extends over a calendar date), the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF.

    Time frame: Day 1-90

  10. Left Ventricular Ejection Fraction

    Change from baseline, measured by echocardiography

    Time frame: Day 1, Day 90

  11. N-terminal pro B-type natriuretic peptide

    blood test measurement of heart failure

    Time frame: Day 90

  12. New York Heart Association Class

    Measurement of cardiac status

    Time frame: Day 90

  13. Kansas City Cardiomyopathy Questionnaire

    Patient-reported outcome measure of health status and function

    Time frame: Day 90

Other outcomes

  1. Pharmacokinetic profile of serum IC14 level, including serum half life and maximum serum concentration

    Serum IC14 levels

    Time frame: baseline, 15 minutes, 6 hours, Day 4, Day 15, Day 22, Day 29

  2. Pharmacodynamics

    Percent monocyte CD14 receptor occupancy

    Time frame: Day 22, Day 29

  3. Immunogenicity

    Anti-drug antibodies

    Time frame: baseline, Day 29, Day 90

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Included in publication supplemental materials and provided to central data base

Supporting information: Study protocol

Time frame: study completion

Access criteria: public access through journal website and/or ClinicalTrials.gov website listing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2025 to primary completion in Aug 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → Aug 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 7, 2024
StartActual
Feb 6, 2025
Primary completionActual
Aug 1, 2026was Jun 2026
CompletionActual
Oct 1, 2026was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Primary completion
Jun 1, 2026→Aug 1, 2026 (actual)
Nov 13, 2026
Study completion
Sep 1, 2026→Oct 1, 2026 (actual)
Nov 13, 2026
Enrollment
10 (estimated)→7 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Active, not recruiting→Completed
    Primary completion Jun 1, 2026→Aug 1, 2026 (now actual)
    Study completion Sep 1, 2026→Oct 1, 2026 (now actual)
    Enrollment 10 (estimated)→7 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06678074
Lead sponsor
Implicit Bioscience
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Feb 6, 2025
Primary completion
Aug 1, 2026
Completion
Oct 1, 2026
Last update
Nov 13, 2026

Study contacts

Marc Sintek, MD
principal investigator · PI
Antonio Abbate, MD, PhD
principal investigator · PI

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atibuclimab

Start the discussion